Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

3.46USD
17 Jul 2019
Change (% chg)

$-0.10 (-2.81%)
Prev Close
$3.56
Open
$3.55
Day's High
$3.58
Day's Low
$3.42
Volume
304,779
Avg. Vol
511,409
52-wk High
$9.94
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Biocryst Reports Q1 2019 Results
Wednesday, 8 May 2019 

May 8 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.28.Q1 REVENUE $5.9 MILLION VERSUS $4.0 MILLION.Q1 REVENUE ESTIMATE $3.1 MILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.BIOCRYST CONTINUES TO EXPECT NET OPERATING CASH USE TO BE IN RANGE OF $105 MILLION TO $130 MILLION FOR 2019.CONTINUES TO EXPECT ITS 2019 OPERATING EXPENSES TO BE IN RANGE OF $120 MILLION TO $145 MILLION.  Full Article

Biocryst Pharmaceuticals Reports Q4 Loss Per Share Of $0.25
Monday, 4 Mar 2019 

March 4 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.25.Q4 REVENUE $2.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $2.8 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.25 -- REFINITIV IBES DATA.CASH, CASH EQUIVALENTS AND INVESTMENTS TOTALED $128.4 MILLION AT DECEMBER 31, 2018.  Full Article

Biocryst Advancing Bcx9930 Into Phase 1 Development
Monday, 4 Mar 2019 

March 4 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST ADVANCING BCX9930, AN ORAL FACTOR D INHIBITOR FOR COMPLEMENT-MEDIATED DISEASES, INTO PHASE 1 DEVELOPMENT.BIOCRYST PHARMACEUTICALS INC - BCX9930 SHOWS HIGH POTENCY, SPECIFICITY, SUPPRESSION OF HEMOLYSIS AND WIDE SAFETY MARGIN IN PRECLINICAL STUDIES.BIOCRYST PHARMACEUTICALS INC - PATIENTS CURRENTLY LIMITED TO INTRAVENOUS (IV) INFUSION THERAPY, OR NO THERAPY.BIOCRYST PHARMACEUTICALS INC - PHASE 1 DATA FROM STUDY EXPECTED IN Q4 2019.  Full Article

Biocryst Strengthens Cash Position With Flexible $100 Million Debt Facility
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST STRENGTHENS CASH POSITION WITH FLEXIBLE $100 MILLION DEBT FACILITY.BIOCRYST PHARMACEUTICALS INC - NEW LOAN FACILITY INCREASES TO $50 MILLION TO FURTHER EXTEND CASH RUNWAY.BIOCRYST PHARMACEUTICALS INC - ADDITIONAL $30 MILLION AVAILABLE AT COMPANY OPTION FOLLOWING POSITIVE PHASE 3 APEX-2 DATA.BIOCRYST PHARMACEUTICALS INC - ANOTHER $20 MILLION AVAILABLE AT COMPANY OPTION FOLLOWING NDA APPROVAL OF BCX7353 FOR HAE PROPHYLAXIS.BIOCRYST PHARMACEUTICALS INC - NEW LOAN FACILITY REPLACES AN EXISTING $30 MILLION SECURED LOAN FACILITY WITH MIDCAP.BIOCRYST PHARMACEUTICALS INC - BIOCRYST IMMEDIATELY ACCESSES $50 MILLION OF NEW LOAN FACILITY, ADDING $20 MILLION OF NON-DILUTIVE CASH..BIOCRYST PHARMACEUTICALS INC - BIOCRYST INTENDS TO FILE AN NDA FOR BCX7353 BY END OF 2019..BIOCRYST PHARMACEUTICALS INC - TERMS OF NEW LOAN FACILITY PROVIDE THAT BIOCRYST WILL BE IN AN INTEREST-ONLY PAYMENT PERIOD THROUGH JUNE 2020.  Full Article

Biocryst Receives $3.5 Mln For Clinical Trials Of Galidesivir In Yellow Fever
Monday, 17 Sep 2018 

Sept 17 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST RECEIVES ADDITIONAL $3.5 MILLION TO FUND CLINICAL TRIALS OF GALIDESIVIR IN YELLOW FEVER.BIOCRYST PHARMACEUTICALS - NIAID DEVELOPMENT CONTRACT FOR GALIDESIVIR NOW TOTALS $43.0 MILLION.  Full Article

Biocryst reports Q2 loss per share $0.19
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.19.Q2 REVENUE $12.5 MILLION VERSUS $3.1 MILLION.Q2 REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.FY 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 MILLION TO $105 MILLION.FY 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 MILLION TO $110 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

U.S. FDA Grants Fast Track Designation For Biocryst’S Bcx7353
Monday, 6 Aug 2018 

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR BIOCRYST’S BCX7353.BIOCRYST PHARMACEUTICALS - FOCUSED ON COMPLETING PHASE 3 PROGRAM & PREPARING FOR NDA FILING FOR BCX7353 IN H2 2019.  Full Article

BioCryst Pharmaceuticals Commences Public Offering Of Common Stock
Thursday, 2 Aug 2018 

Aug 1 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS COMMENCES PUBLIC OFFERING OF COMMON STOCK.  Full Article

Biocryst Pharmaceuticals Entered $30 Million Secured Loan Facility
Saturday, 21 Jul 2018 

July 20 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO, UNITS, ENTERED A $30 MILLION SECURED LOAN FACILITY - SEC FILING.BIOCRYST PHARMACEUTICALS - USING PROCEEDS OF NEW LOAN TO PAY OFF OUTSTANDING AMOUNTS UNDER PRIOR CREDIT AGREEMENT.  Full Article

Biocryst Provides Update On Strategy, Pipeline And Outlook
Wednesday, 11 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PROVIDES UPDATE ON STRATEGY, PIPELINE AND OUTLOOK.BIOCRYST PHARMACEUTICALS INC - CONTINUE TO EXPECT TO REPORT TOP-LINE RESULTS FROM 750 MG COHORT IN Q3 OF 2018.BIOCRYST PHARMACEUTICALS INC - EXECUTING A STRATEGIC PLAN.BIOCRYST - ON TRACK FOR H1 2019 INITIATION OF PHASE 1 CLINICAL TRIAL FOR ALK-2 INHIBITOR PROGRAM FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.BIOCRYST PHARMACEUTICALS INC - HAS REVISED ITS STAND-ALONE 2018 GUIDANCE AND EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.BIOCRYST PHARMACEUTICALS INC - 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 TO $110 MILLION.BIOCRYST PHARMACEUTICALS INC - EXPECT TO REPORT TOP-LINE RESULTS FROM ZENITH-1 750 MG COHORT IN Q3 2018.BIOCRYST PHARMACEUTICALS INC - EXPECTS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.  Full Article